Scientific and Therapeutic Aspects of Botulinum Toxin

by Mitchell F. Brin; Joseph Jankovic; Mark Hallett

• ISBN13: 9780781732673
• ISBN10: 0781732670
• Format: Hardcover
• Copyright: 2002-06-01
• Publisher: Lippincott Williams & Wilkins

Summary

Written by an international group of noted basic scientists and clinicians, this volume presents state-of-the-art information on the mechanisms of action, pharmacology, neurophysiological effects, and therapeutic uses of botulinum neurotoxins. A major portion of the book reviews recent clinical experience and clinical trials with botulinum toxin therapy for strabismus, dystonia, juvenile cerebral palsy, spasticity, hyperhidrosis, gastrointestinal and genitourinary disorders, headache, cosmetic facial conditions, and various disorders involving excessive muscle contraction or pain. Other chapters examine the immunology of botulinum toxins, the use of other chemodenervating agents, and the development of novel neurotoxin constructs.

Table of Contents

I. Basic Sciences: Mechanism of Action
The Metalloprotease Activity of Tetanus and Botulinum Neurotoxins	3	(8)
Ornella Rossetto
Paola Caccin
Michela Rigoni
Michela Seveso
Fiorella Tonello
Cesare Montecucco
Structural View of Botulinum Neurotoxin in Numerous Functional States	11	(18)
Michael A. Hanson
Raymond C. Stevens
Crystal Structure of Clostridium botulinum Neurotoxin Serotype B	29	(12)
Subramanyam Swaminathan
Subramaniam Eswaramoorthy
The Receptor Binding Domains of Clostridial Neurotoxins	41	(8)
J. Mark Sutton
Lindsey Spaven
Nigel J. Silman
Bassam Hallis
Oliver Chow-Worn
Clifford C. Shone
Neurospecific Binding and Trafficking of Tetanus Toxin	49	(12)
Giovanna Lalli
Judit Herreros
Giampietro Schiavo
Botulinum Neurotoxin A and Synaptic Vesicle Trafficking	61	(14)
Elaine A. Neale
Molecular Basis of the Unique Endopeptidase Activity of Botulinum Neurotoxin	75	(16)
Bal Ram Singh
II. Pharmacology of Botulinum Neurotoxins
Insights into the Extended Duration of Neuroparalysis by Botulinum Neurotoxin A Relative to the Other Shorter-Acting Serotypes: Differences Between Motor Nerve Terminals and Cultured Neurons	91	(12)
J. Oliver Dolly
Godfrey Lisk
Patrick G. Foran
Frederic Meunier
Nadiem Mohammed
G. O'Sullivan
Anton de Paiva
Immunologic and Other Properties of Therapeutic Botulinum Toxin Serotypes	103	(12)
K. Roger Aoki
Production, Quality, and Stability of Botulinum Toxin Type B (MYOBLOC™) for Clinical Use	115	(8)
James E. Callaway
Andrew J. Grethlein
Spread of Paralysis to Nearby and Distant Noninjected Muscles in a Monkey Hand Model: Comparison of BoNT-B and BoNT-A	123	(12)
Joseph C. Arezzo
Mona S. Litwak
Florence A. Caputo
Kathleen E. Meyer
George M. Shopp
The Glycogen Depletion Assay and the Measurement of Botulinum Toxin Injections	135	(10)
Asif Amirali
Ira Sanders
III. Clinical Diseases
Clinical Botulism	145	(6)
Stephen S. Arnon
Clinical Aspects of Tetanus	151	(16)
John C. Morgan
Thomas P. Bleck
IV. Neurophysiology
Effects of Botulinum Toxin at the Neuromuscular Junction	167	(4)
Mark Hallett
Effects of Botulinum Toxin Type A on Central Nervous System Function	171	(8)
Alfredo Berardelli
Francesca Gilio
Antonio Curra
Impact of Botulinum Toxin on Laryngeal Physiology	179	(10)
Christy L. Ludlow
V. Clinical Therapeutics
The Role of Botulinum Toxin Type A in the Management of Strabismus	189	(8)
Alan Scott
The Role of Botulinum Toxin Type A (BOTOX®) in the Management of Blepharospasm and Hemifacial Spasm	197	(10)
Joseph A. Mauriello, Jr.
Botulinum Toxin Type A Injections for the Management of the Hyperfunctional Larynx	207	(10)
Andrew Blitzer
Craig Zalvan
Omar Gonzalez-Yanez
Mitchell F. Brin
The Use of Botulinum Toxin in Juvenile Cerebral Palsy	217	(6)
Mauricio R. Delgado
Botulinum Toxin Type A in the Treatment of Spasticity	223	(10)
A.P. Moore
Botulinum Toxin Type A BOTOX® for Pain and Headache	233	(18)
Mitchell F. Brin
William Binder
Andrew Blitzer
Lawrence Schenrock
Janice M. Pogoda
The Role of Botulinum Toxin Type A in the Management of Occupational Dystonia and Writer's Cramp	251	(8)
Barbara Illowsky Karp
Botulinum Toxin A Therapy for Temporomandibular Disorders	259	(10)
Marvin Schwartz
Brian Freund
The Role of Botulinum Toxin in Gastrointestinal Disorders	269	(18)
Giuseppe Brisinda
Giorgio Maria
Anna Rita Bentivoglio
Alberto Albanese
Botulinum Toxin Type A in the Treatment of Hyperfunctional Facial Lines and Cosmetic Disorders	287	(8)
Alastair Carruthers
Jean Carruthers
Botulinum Toxin for Achalasia and Related Disorders	295	(8)
Willemijntje A. Hoogerwerf
Dennis D. Dykstra
Pankaj J. Pasricha
Treatment of Focal Hyperhidrosis with Botulinum Toxin A	303	(6)
Markus Naumann
The Use of Botulinum Toxins in the Management of Myofascial Pain and Other Conditions Associated with Painful Muscle Spasm	309	(14)
Mike A. Royal
Botulinum Toxin Treatment in Tremors	323	(14)
Jyh-Gong Hou
Joseph Jankovic
Botulinum Toxin in the Treatment of Tics	337	(6)
Carolyn N. Kwak
Joseph Jankovic
Botulinum Toxin Type A in the Management of Oromandibular Dystonia and Bruxism	343	(8)
Ron Tintner
Joseph Jankovic
Use of Botulinum Toxin in Urologic Disorders	351	(8)
Dennis D. Dykstra
VI. Clinical Trials
Cervical Dystonia: Treatment with Botulinum Toxin Serotype A as BOTOX® or Dysport®	359	(6)
Cynthia L. Comella
Studies with Dysport® in Cervical Dystonia	365	(6)
Werner Poewe
Tanja Entner
Review of Clinical Efficacy Studies with Botulinum Toxin Type B (MYOBLOC™) for Cervical Dystonia	371	(14)
Stewart A. Factor
VII. Immunology of Botulinum Toxin
Immune Recognition and Cross-Reactivity of Botulinum Neurotoxins	385	(24)
M. Zouhair Atassi
Botulinum Toxin: Clinical Implications of Antigenicity and Immunoresistance	409	(8)
Joseph Jankovic
Managing Patients with Botulinum Toxin Antibodies	417	(10)
Dirk Dressler
Vaccines for Preventing Botulism	427	(14)
Leonard A. Smith
Michael P. Byrne
VIII. Other Serotypes and Chemodenervating Agents
Botulinum Neurotoxin Serotypes C and E: Clinical Trials	441	(10)
Roberto Eleopra
Valeria Tugnoli
Rocco Quatrale
Ornella Rossetto
Cesare Montecucco
Domenico De Grandis
Long-Term Use of Botulinum Toxin Type F to Treat Patients Resistant to Botulinum Toxin Type A	451	(4)
Paul E. Greene
Muscle Afferent Block for Dystonia: Implications for the Physiological Mechanism of Action of Botulinum Toxin	455	(4)
Ryuji Kaji
Electromyography-Guided Chemodenervation with Phenol in Cervical Dystonia (Spasmodic Torticollis)	459	(4)
Janice M. Massey
Immunotoxin	463	(6)
Mark Hallett
IX. Novel Toxin Constructs
Hybrid and Chimeric Botulinum Toxin Molecules	469	(8)
Eric A. Johnson
Michael C. Goodnough
Carl M. Malizio
William H. Tepp
Sean S. Dineen
Marite Bradshaw
Novel Toxin Developments: Delivery of Endopeptidase Activity of Botulinum Neurotoxin to New Target Cells	477	(8)
Keith A. Foster
Neuronal Delivery Vectors Derived from Tetanus Toxin	485	(10)
Paul S. Fishman
Index	495